Rate Of ReturnHIMS 国际布局
Although HIMS's stock price has been sluggish recently,
I think the overall direction is good, expanding into Canada and Europe and enriching the product line. Revenue growth is still at 50%.
The focus later will be on the benefits of the acquisition, i.e., whether it will contribute significantly to business growth.
The CEO is also confident about the 2030 guidance. Just hold on and consider increasing your position in $Hims & Hers Health(HIMS.US)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
